These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23219017)

  • 41. Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.
    Zhang R; Shao C; Huo N; Li M; Xu X
    Gut Liver; 2016 May; 10(3):446-55. PubMed ID: 26470765
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population.
    Imran M; Manzoor S; Azam S; Resham S
    APMIS; 2015 Apr; 123(4):342-9. PubMed ID: 25703417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.
    Barreiro P; Pineda JA; Rallón N; Naggie S; Martín-Carbonero L; Neukam K; Rivero A; Benito JM; Caruz A; Vispo E; Camacho A; Medrano J; McHutchison J; Soriano V
    J Infect Dis; 2011 Jun; 203(11):1629-36. PubMed ID: 21592993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between the genetic variation in interleukin 28B and response to antiviral therapy in patients with chronic hepatitis C.
    Xie JQ; Guo XY; Zhang XH; Lin BL; Xie DY; Gao ZL; Wang GS; Zhao ZX
    Chin Med J (Engl); 2012 Jul; 125(13):2334-8. PubMed ID: 22882858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study of Interleukin 28B rs12979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients.
    Ea R; Aa G; Ag ES; Ma A
    Egypt J Immunol; 2015 Jun; 22(2):57-68. PubMed ID: 28502145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
    Bochud PY; Bibert S; Negro F; Haagmans B; Soulier A; Ferrari C; Missale G; Zeuzem S; Pawlotsky JM; Schalm S; Hellstrand K; Neumann AU; Lagging M
    J Hepatol; 2011 Nov; 55(5):980-8. PubMed ID: 21354446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
    Ling Q; Chen J; Zhou H; Zhong J; Chen Y; Ye Q; Zhuo Y; Min N; Shang B
    Arch Virol; 2015 Apr; 160(4):1105-12. PubMed ID: 25687192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
    Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
    J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients.
    Naeemi H; Aslam R; Raza SM; Shahzad MA; Naz S; Manzoor S; Khaliq S
    Arch Virol; 2018 Apr; 163(4):997-1008. PubMed ID: 29340806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection.
    Abdelwahab SF; Zakaria Z; Allam WR; Hamdy S; Mahmoud MA; Sobhy M; Rewisha E; Waked I
    Arch Virol; 2015 Nov; 160(11):2833-7. PubMed ID: 26280523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C.
    Murakawa M; Asahina Y; Nakagawa M; Sakamoto N; Nitta S; Kusano-Kitazume A; Watanabe T; Kawai-Kitahata F; Otani S; Taniguchi M; Goto F; Nishimura-Sakurai Y; Itsui Y; Azuma S; Kakinuma S; Watanabe M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1075-84. PubMed ID: 25611696
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
    J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
    Jiménez-Sousa MA; Berenguer J; Rallón N; Pineda-Tenor D; Aldamiz-Echevarria T; Soriano V; García-Álvarez M; Vazquez-Morón S; Restrepo C; Carrero A; Benito JM; Resino S
    Liver Int; 2016 Sep; 36(9):1258-66. PubMed ID: 26836972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of cytokine gene (IFN-γ, TNF-α, TGF-β1, IL-6, and IL-10) polymorphisms in pathogenesis of acute rheumatic fever in Turkish children.
    Col-Araz N; Pehlivan S; Baspinar O; Oguzkan-Balci S; Sever T; Balat A
    Eur J Pediatr; 2012 Jul; 171(7):1103-8. PubMed ID: 22350281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
    Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
    J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4.
    Attallah AM; Omran D; Marie MS; Abdelrazek M; Salama A; El Essawey R; Mobarak L; Maklad S; Omar A
    Br J Biomed Sci; 2018 Oct; 75(4):157-162. PubMed ID: 29914308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis.
    Alhamad EH; Cal JG; Shakoor Z; Almogren A; AlBoukai AA
    BMC Med Genet; 2013 Jul; 14():66. PubMed ID: 23815594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.